{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:43:55Z","timestamp":1791495835010,"version":"4.3.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T00:00:00Z","timestamp":1573084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T00:00:00Z","timestamp":1573084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Immunol"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1038\/s41423-019-0321-2","type":"journal-article","created":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T11:05:58Z","timestamp":1573124758000},"page":"272-282","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["LILRB4 ITIMs mediate the T cell suppression and infiltration of acute myeloid leukemia cells"],"prefix":"10.1038","volume":"17","author":[{"given":"Zunling","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changzhu","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoye","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Licai","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali H.","family":"Sadek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng Cheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,7]]},"reference":[{"key":"321_CR1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/15384101.2015.1121324","volume":"15","author":"X Kang","year":"2016","unstructured":"Kang, X. et al. Inhibitory leukocyte immunoglobulin-like receptors: immune checkpoint proteins and tumor sustaining factors. Cell Cycle 15, 25\u201340 (2016).","journal-title":"Cell Cycle"},{"key":"321_CR2","doi-asserted-by":"crossref","unstructured":"Hirayasu, K. & Arase, H. Functional and genetic diversity of leukocyte immunoglobulin-like receptor and implication for disease associations. J. Hum. Genet. 60, 703\u2013708 (2015).","DOI":"10.1038\/jhg.2015.64"},{"key":"321_CR3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/imr.12314","volume":"267","author":"J Trowsdale","year":"2015","unstructured":"Trowsdale, J., Jones, D. C., Barrow, A. D. & Traherne, J. A. Surveillance of cell and tissue perturbation by receptors in the LRC. Immunol. Rev. 267, 117\u2013136 (2015).","journal-title":"Immunol. Rev."},{"key":"321_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1600-065X.2008.00666.x","volume":"224","author":"M Daeron","year":"2008","unstructured":"Daeron, M., Jaeger, S., Du Pasquier, L. & Vivier, E. Immunoreceptor tyrosine-based inhibition motifs: a quest in the past and future. Immunol. Rev. 224, 11\u201343 (2008).","journal-title":"Immunol. Rev."},{"key":"321_CR5","doi-asserted-by":"publisher","first-page":"275302","DOI":"10.1155\/2011\/275302","volume":"2011","author":"T Takai","year":"2011","unstructured":"Takai, T., Nakamura, A. & Endo, S. Role of PIR-B in autoimmune glomerulonephritis. J. Biomed. Biotechnol. 2011, 275302 (2011).","journal-title":"J. Biomed. Biotechnol."},{"key":"321_CR6","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S0065-2776(06)91007-4","volume":"91","author":"HR Katz","year":"2006","unstructured":"Katz, H. R. Inhibition of inflammatory responses by leukocyte Ig-like receptors. Adv. Immunol. 91, 251\u2013272 (2006).","journal-title":"Adv. Immunol."},{"key":"321_CR7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/bs.ai.2015.04.001","volume":"127","author":"ED Carosella","year":"2015","unstructured":"Carosella, E. D., Rouas-Freiss, N., Roux, D. T., Moreau, P. & LeMaoult, J. HLA-G: an Immune Checkpoint Molecule. Adv. Immunol. 127, 33\u2013144 (2015).","journal-title":"Adv. Immunol."},{"key":"321_CR8","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1002\/cyto.b.20164","volume":"72","author":"AI Colovai","year":"2007","unstructured":"Colovai, A. I. et al. Expression of inhibitory receptor ILT3 on neoplastic B cells is associated with lymphoid tissue involvement in chronic lymphocytic leukemia. Cytom. Part B, Clin. Cytom. 72, 354\u2013362 (2007).","journal-title":"Cytom. Part B, Clin. Cytom."},{"key":"321_CR9","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1182\/blood-2017-03-775858","volume":"130","author":"V Zurli","year":"2017","unstructured":"Zurli, V. et al. Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia. Blood 130, 2006\u20132017 (2017).","journal-title":"Blood"},{"key":"321_CR10","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nature11095","volume":"485","author":"J Zheng","year":"2012","unstructured":"Zheng, J. et al. Inhibitory receptors bind ANGPTLs and support blood stem cells and leukaemia development. Nature 485, 656\u2013660 (2012).","journal-title":"Nature"},{"key":"321_CR11","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/ncb3158","volume":"17","author":"X Kang","year":"2015","unstructured":"Kang, X. et al. The ITIM-containing receptor LAIR1 is essential for acute myeloid leukaemia development. Nat. Cell Biol. 17, 665\u2013677 (2015).","journal-title":"Nat. Cell Biol."},{"key":"321_CR12","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41586-018-0615-z","volume":"562","author":"M Deng","year":"2018","unstructured":"Deng, M. et al. LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature 562, 605\u2013609 (2018).","journal-title":"Nature"},{"key":"321_CR13","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1016\/j.ymthe.2018.08.001","volume":"26","author":"S John","year":"2018","unstructured":"John, S. et al. A novel anti-LILRB4 CAR-T cell for the treatment of monocytic AML. Mol. Ther. 26, 2487\u20132495 (2018).","journal-title":"Mol. Ther."},{"key":"321_CR14","doi-asserted-by":"publisher","first-page":"7432","DOI":"10.4049\/jimmunol.178.11.7432","volume":"178","author":"N Suciu-Foca","year":"2007","unstructured":"Suciu-Foca, N. et al. Soluble Ig-like transcript 3 inhibits tumor allograft rejection in humanized SCID mice and T cell responses in cancer patients. J. Immunol. 178, 7432\u20137441 (2007).","journal-title":"J. Immunol."},{"key":"321_CR15","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41590-017-0004-z","volume":"19","author":"AA Barkal","year":"2018","unstructured":"Barkal, A. A. et al. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nat. Immunol. 19, 76\u201384 (2018).","journal-title":"Nat. Immunol."},{"key":"321_CR16","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nature14231","volume":"521","author":"Z Chen","year":"2015","unstructured":"Chen, Z. et al. Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. Nature 521, 357\u2013361 (2015).","journal-title":"Nature"},{"key":"321_CR17","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.ccell.2017.09.004","volume":"32","author":"F Perna","year":"2017","unstructured":"Perna, F. et al. Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML. Cancer Cell 32, 506\u2013519 e505 (2017).","journal-title":"Cancer Cell"},{"key":"321_CR18","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1084\/jem.185.10.1743","volume":"185","author":"M Cella","year":"1997","unstructured":"Cella, M. et al. A novel inhibitory receptor (ILT3) expressed on monocytes, macrophages, and dendritic cells involved in antigen processing. J. Exp. Med. 185, 1743\u20131751 (1997).","journal-title":"J. Exp. Med."},{"key":"321_CR19","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/intimm\/dxv009","volume":"27","author":"M Inui","year":"2015","unstructured":"Inui, M. et al. Human CD43+ B cells are closely related not only to memory B cells phenotypically but also to plasmablasts developmentally in healthy individuals. Int Immunol. 27, 345\u2013355 (2015).","journal-title":"Int Immunol."},{"key":"321_CR20","doi-asserted-by":"crossref","unstructured":"Dobrowolska, H., Vlad, G. & Suciu-Foca, N. Expression of inhibitory receptor ILT3 on normal hematopoietic stem cells and leukemic progenitors. J. Cell Sci. Ther. 4, 98 (2013).","DOI":"10.4172\/2157-7013.S1.025"},{"key":"321_CR21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/cyto.b.21050","volume":"84","author":"H Dobrowolska","year":"2013","unstructured":"Dobrowolska, H. et al. Expression of immune inhibitory receptor ILT3 in acute myeloid leukemia with monocytic differentiation. Cytom. Part B, Clin. Cytom. 84, 21\u201329 (2013).","journal-title":"Cytom. Part B, Clin. Cytom."},{"key":"321_CR22","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1158\/2326-6066.CIR-19-0036","volume":"7","author":"X Gui","year":"2019","unstructured":"Gui, X. et al. Disrupting LILRB4\/APOE interaction by an efficacious humanized antibody reverses T-cell suppression and blocks AML development. Cancer Immunol. Res. 7, 1244\u20131257 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"321_CR23","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1161\/ATVBAHA.111.222745","volume":"31","author":"D Baitsch","year":"2011","unstructured":"Baitsch, D. et al. Apolipoprotein E induces antiinflammatory phenotype in macrophages. Arteriosclerosis, Thrombosis, Vasc. Biol. 31, 1160\u20131168 (2011).","journal-title":"Arteriosclerosis, Thrombosis, Vasc. Biol."},{"key":"321_CR24","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/eji.1830270313","volume":"27","author":"J Samaridis","year":"1997","unstructured":"Samaridis, J. & Colonna, M. Cloning of novel immunoglobulin superfamily receptors expressed on human myeloid and lymphoid cells: structural evidence for new stimulatory and inhibitory pathways. Eur. J. Immunol. 27, 660\u2013665 (1997).","journal-title":"Eur. J. Immunol."},{"key":"321_CR25","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1177\/1753425917699465","volume":"23","author":"M Park","year":"2017","unstructured":"Park, M. et al. A dual positive and negative regulation of monocyte activation by leukocyte Ig-like receptor B4 depends on the position of the tyrosine residues in its ITIMs. Innate Immun. 23, 381\u2013391 (2017).","journal-title":"Innate Immun."},{"key":"321_CR26","first-page":"631","volume":"103","author":"M Ishige","year":"2012","unstructured":"Ishige, M. et al. A case of metastatic spermatic cord tumor from acute myelogenous leukemia. Nihon Hinyokika Gakkai zasshi Jpn. J. Urol. 103, 631\u2013635 (2012).","journal-title":"Nihon Hinyokika Gakkai zasshi Jpn. J. Urol."},{"key":"321_CR27","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/00005792-198011000-00002","volume":"59","author":"DJ Straus","year":"1980","unstructured":"Straus, D. J. et al. The acute monocytic leukemias: multidisciplinary studies in 45 patients. Medicine 59, 409\u2013425 (1980).","journal-title":"Medicine"},{"key":"321_CR28","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1046\/j.1432-1327.2000.01350.x","volume":"267","author":"Y Wang","year":"2000","unstructured":"Wang, Y. et al. Identification of a novel nuclear factor-kappaB sequence involved in expression of urokinase-type plasminogen activator receptor. Eur. J. Biochem. 267, 3248\u20133254 (2000).","journal-title":"Eur. J. Biochem."},{"key":"321_CR29","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.immuni.2005.01.004","volume":"22","author":"H Zhang","year":"2005","unstructured":"Zhang, H., Meng, F., Chu, C. L., Takai, T. & Lowell, C. A. The Src family kinases Hck and Fgr negatively regulate neutrophil and dendritic cell chemokine signaling via PIR-B. Immunity 22, 235\u2013246 (2005).","journal-title":"Immunity"},{"key":"321_CR30","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.4049\/jimmunol.168.7.3351","volume":"168","author":"T Bellon","year":"2002","unstructured":"Bellon, T., Kitzig, F., Sayos, J. & Lopez-Botet, M. Mutational analysis of immunoreceptor tyrosine-based inhibition motifs of the Ig-like transcript 2 (CD85j) leukocyte receptor. J. Immunol. 168, 3351\u20133359 (2002).","journal-title":"J. Immunol."},{"key":"321_CR31","doi-asserted-by":"publisher","first-page":"5694","DOI":"10.1182\/blood-2007-12-126748","volume":"111","author":"A Munitz","year":"2008","unstructured":"Munitz, A., McBride, M. L., Bernstein, J. S. & Rothenberg, M. E. A dual activation and inhibition role for the paired immunoglobulin-like receptor B in eosinophils. Blood 111, 5694\u20135703 (2008).","journal-title":"Blood"},{"key":"321_CR32","doi-asserted-by":"publisher","first-page":"5791","DOI":"10.1074\/jbc.274.9.5791","volume":"274","author":"JM Lu-Kuo","year":"1999","unstructured":"Lu-Kuo, J. M., Joyal, D. M., Austen, K. F. & Katz, H. R. gp49B1 inhibits IgE-initiated mast cell activation through both immunoreceptor tyrosine-based inhibitory motifs, recruitment of src homology 2 domain-containing phosphatase-1, and suppression of early and late calcium mobilization. J. Biol. Chem. 274, 5791\u20135796 (1999).","journal-title":"J. Biol. Chem."},{"key":"321_CR33","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/ni760","volume":"3","author":"CC Chang","year":"2002","unstructured":"Chang, C. C. et al. Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat. Immunol. 3, 237\u2013243 (2002).","journal-title":"Nat. Immunol."},{"key":"321_CR34","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.humimm.2014.10.012","volume":"75","author":"L Cousens","year":"2014","unstructured":"Cousens, L., Najafian, N., Martin, W. D. & De Groot, A. S. Tregitope: immunomodulation powerhouse. Hum. Immunol. 75, 1139\u20131146 (2014).","journal-title":"Hum. Immunol."},{"key":"321_CR35","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.4049\/jimmunol.1700553","volume":"200","author":"Z Xu","year":"2018","unstructured":"Xu, Z. et al. ILT3.Fc-CD166 interaction induces inactivation of p70 S6 kinase and inhibits tumor cell growth. J. Immunol. 200, 1207\u20131219 (2018).","journal-title":"J. Immunol."}],"updated-by":[{"DOI":"10.1038\/s41423-019-0351-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T00:00:00Z","timestamp":1580428800000}}],"container-title":["Cellular &amp; Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41423-019-0321-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41423-019-0321-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41423-019-0321-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T11:05:06Z","timestamp":1670670306000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41423-019-0321-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,7]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["321"],"URL":"https:\/\/doi.org\/10.1038\/s41423-019-0321-2","relation":{},"ISSN":["1672-7681","2042-0226"],"issn-type":[{"value":"1672-7681","type":"print"},{"value":"2042-0226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,7]]},"assertion":[{"value":"30 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An amendment to this paper has been published and can be accessed via a link at the top of the paper.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.C.Z. is a scientific founder of Immune-Onc Therapeutics. C.C.Z. and M.D.\u00a0hold\u00a0equity in and have\u00a0multiple patents licensed to Immune-Onc Therapeutics. The other\u00a0authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}